Related Experiment Video
Updated: Dec 12, 2025

09:57
How to Measure Cortical Folding from MR Images: a Step-by-Step Tutorial to Compute Local Gyrification Index
Published on: January 2, 2012
28.4K
Cortical thickness in Parkinson disease: A coordinate-based meta-analysis
LiQin Sheng1, PanWen Zhao2, HaiRong Ma1
1Department of Neurology, Kunshan Hospital of Traditional Chinese Medicine, Kunshan.
Medicine
|August 7, 2020
Summary
This meta-analysis synthesizes surface-based morphometry studies to reveal consistent gray matter cortical thickness (CTh) changes in Parkinson disease (PD). Findings may aid in developing biomarkers for PD brain morphometry.
Area of Science:
- Neuroimaging
- Neuroscience
- Neurology
Background:
- Surface-based morphometry (SBM) studies investigating gray matter cortical thickness (CTh) in Parkinson disease (PD) show inconsistent results.
- A systematic review is needed to clarify CTh alterations in PD.
- Coordinate-based meta-analysis (CBMA) is an updated tool for integrating SBM studies.
Purpose of the Study:
- To systematically review and synthesize evidence on CTh abnormalities in PD using CBMA.
- To identify consistent patterns of CTh alterations in PD across studies.
- To explore the potential for CTh alterations as biomarkers for PD.
Main Methods:
- Comprehensive literature search of multiple databases (PubMed, Embase, Web of Science, CNKI, WanFang, SinoMed) up to February 2, 2020.
- Inclusion of SBM studies comparing regional CTh between PD patients and healthy controls using SDM-PSI.
- Conducting main CBMA with supplementary analyses including jackknife, subgroup, heterogeneity, publication bias, and meta-regression analyses.
Main Results:
- The coordinate-based meta-analysis will provide the most current evidence regarding CTh alterations in Parkinson disease.
- Expected to identify specific regions of significant CTh changes in PD patients compared to controls.
Conclusions:
- Consistent and robust evidence of CTh alterations is expected to characterize brain morphometry in PD.
- These findings may contribute to the development of reliable biomarkers for Parkinson disease.
Related Concept Videos
Parkinson's Disease: Overview
1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
Parkinson's Disease: Treatment
824
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
824
Neural Regulation
42.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.7K

